Former Lilly Executive will oversee Development, Regulatory Affairs and Quality

BOSTON, Feb. 22, 2018 /PRNewswire/

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it appointed Colleen Mockbee to serve as the company’s Chief Development Officer. In her role as CDO, Ms. Mockbee will oversee development, regulatory and quality activities and serve on the Company’s executive management team.

Ms. Mockbee joins PTx following a 20-year career as a leader and executive overseeing multiple areas of drug development at Eli Lilly and Company. ...

Purchase includes Lynnwood, WA Biologics Manufacturing Facility 

BOSTON, MA – February 1, 2018/ PR Newswire/

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the ...

Funds to support pipeline development and commercial operations 

BOSTON, MA – February 1, 2018/ PR Newswire/

Partner Therapeutics, Inc. (PTx) announced today the closing of a Series A financing to support the launch and growth of the company. PTx is an oncology company focused on the development and commercialization of approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care.

The financing totaled $60 million and was led by a group of pre-eminent biopharma investors, including Perceptive Advisors, ...